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Abstract Previous studies have suggested that human salivary
secretory leukocyte protease inhibitor (SLPI) inhibits HIV-1 by
binding to a host cell surface protein of unknown identity. Using
the yeast two-hybrid assay, we identified a gene sequence
encoding a novel SLPI-binding protein (SLPI-BP). The 1.5-kb
cDNA encodes a 318-amino acid protein with a predicted
transmembrane segment near the C-terminus. Sequence analysis
revealed that SLPI-BP is the human scramblase protein that is
involved in the movement of membrane phospholipids. Co-
expression of SLPI and SLPI-BP followed by an S-protein
pulldown assay confirmed the specific interaction between these
two proteins. Our data represent the first report for the identity
of SLPI-BP. ß 2000 Federation of European Biochemical So-
cieties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The secretory leukocyte protease inhibitor (SLPI) is a serine
protease inhibitor found in £uids lining mucosal surfaces.
Human salivary SLPI was ¢rst identi¢ed in parotid saliva as
a protein immunologically related to the bronchial mucus leu-
kocyte protease inhibitor [1]. The protein consists of two ho-
mologous cysteine-rich domains [2] and exhibits inhibitory
activity against neutrophil elastase, chymotrypsin, trypsin
and cathepsin G [1,3]. In addition to its anti-protease and
anti-in£ammatory activities, salivary SLPI is also a potent
HIV-1 inhibitor that inhibits HIV-1 infection in macrophages
at physiological concentrations [4]. However, SLPI does not
appear to bind HIV-1 viral particle, inhibit HIV-1 reverse
transcriptase or protease, or transduce an activation signal
or downregulate expression of the HIV-1 receptor, CD4 [4].
Rather, its target may be a host cell-associated molecule
whose identity is presently not known [4,5].
In this study, we report the identi¢cation of a cDNA en-
coding a SLPI-binding protein (SLPI-BP) by the in vivo yeast
two-hybrid analysis. Our results indicate that scramblase, a
membrane protein responsible for the dynamic movement of
membrane phospholipids (PLs), interacts with SLPI. The po-
tential role of scramblase in HIV pathogenesis is discussed.
2. Materials and methods
2.1. Materials
The pCI-neo vector was purchased from Promega (Madison, WI,
USA). The Matchmaker Two-Hybrid System-2 kit was purchased
from Clontech (Palo Alto, CA, USA). The Thermo Sequenase 33P-
labeled Terminator Cycle Sequencing Kit was purchased from
Amersham (Arlington Heights, IL, USA). The lipofectamine reagent
was purchased from Life Technologies (Grand Island, NY, USA).
S-protein agarose was purchased from Novagen (Madison, WI,
USA).
2.2. Plasmid construction
To generate the GAL4 DNA-binding domain (BD)^SLPI hybrid
construct, a recombinant baculovirus shuttle vector containing SLPI
cDNA [6] was used as a template in a polymerase chain reaction
(PCR) to incorporate an NcoI restriction site downstream to the
SLPI signal peptide sequence. The 400-bp ampli¢ed SLPI cDNA
was puri¢ed from agarose gel and subcloned into the NcoI/PstI sites
of the pAS2-1 to obtain pAS2-1/SLPI. To construct the SLPI mam-
malian expression vector, the DNA fragment encoding for a His-S-tag
SLPI fusion protein was isolated from our previously constructed
Escherichia coli expression vector pET30C(+) and subcloned into
the XbaI/NotI sites of pCI-neo plasmid to obtain the pCI-neo/His-S-
SLPI. To construct the SLPI-BP mammalian expression vector, the
SLPI-BP cDNA was ¢rst subcloned into a previously constructed
pCI-neo/T7-P82 plasmid that contains a T7-tag sequence upstream
of the multiple cloning sites [7]. The resulting T7-SLPI-BP DNA frag-
ment was then subcloned into the XbaI/NotI sites of the pCI-neo
plasmid to create pCI-neo/T7-SLPI-BP.
2.3. Yeast two-hybrid screening of the peripheral blood leukocyte
cDNA library
To identify leukocytic proteins that interact with salivary SLPI, the
Matchmaker Two-Hybrid System-2 kit was used. The full-length
SLPI cDNA inserted into the GAL4 DNA-BD vector pAS2-1 was
used as bait in screening of the phytohemagglutinin-stimulated human
leukocyte cDNA library (library size 3U106) that was fused to the
GAL4 activation domain (AD) vector pGAD10. The GAL4 BD/SLPI
hybrid construct (i.e. pAS2-1/SLPI) and the AD/leukocyte library
hybrids were co-transformed into yeast strain CG-1945 (Trp3,
Leu3) for library screening. Transformants were selected for those
that contain both types of plasmids with both functional TRP1 and
LEU2 gene restored (i.e. Trp, Leu) and also express interacting
hybrid proteins (i.e. His). Primary His transformants were then
tested for true interacting clones by screening for expression of the
second reconstituted reporter gene lacZ in a L-galactosidase assay as
described below. Plasmids from putative HisLacZ positive clones
were isolated from the yeast and then individually transformed into
E. coli HB101 cells for ampli¢cation. To eliminate false positive, these
plasmids were separately introduced into either the CG-1945 or Y187
yeast strains. The resulting yeast transformants were then tested by
either sequential transformation or yeast mating assay with yeast
strains containing the GAL4 BD/SLPI. The co-transformant diploid
cells were tested for L-galactosidase activity. Only the plasmids that
conferred positive expression were analyzed. Clones containing cDNA
for possible SLPI-BP of interest were screened by PCR and the am-
pli¢cation products were analyzed in 1% agarose gel to estimate the
size.
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Subsequently, plasmids were harvested from the positive clones and
re-examined for their ability to bind to SLPI in S-protein pulldown
assays. The sequence of the positive cDNA clones was determined by
dideoxynucleotides chain termination method using the Thermo Se-
quenase 33P-labeled Terminator Cycle Sequencing Kit and was ana-
lyzed by the BLAST Network Service at NCBI.
2.4. Filter lift LacZ assay
The ¢lter-lift LacZ assay is a qualitative blue/white screening pro-
cedure. We performed this assay to screen for reconstitution of the
LacZ reporter gene in cotransformants that survive the HIS3 growth
selection in a GAL4 two-hybrid library screening. The His colonies
of the yeast strain CG-1945 were patched on synthetic dextrose (SD)
dropout plates (Trp3, Leu3 and His3) supplemented with 5 mM 3-
AT. The plates were incubated at 30‡C for 1^2 days. A dry sterile
Whatman #5 ¢lter was placed over the surface of colonies to be
assayed and then transferred to a pool of liquid nitrogen for 10 s
followed by thawing at room temperature to permeabilize the cells.
The ¢lter was placed on a ¢lter presoaked in 2.5^5 ml of Z bu¡er/X-
gal solution at 30‡C and checked periodically for the appearance of
blue colonies.
2.5. Yeast mating assay
pAS2-1/SLPI and control plasmids (pAS2-1 and pLAM5P (a hybrid
plasmid expressing a fusion of the DNA-BD and an unrelated pro-
tein)) were separately transformed into yeast strain Y187 (MATK),
while each candidate AD/library plasmid to be tested was transformed
into yeast strain CG-1945 (MATa). The resulting Trp Leu trans-
formants were allowed to mate in 0.5 ml of YPD medium at 30‡C
with shaking at 250 rpm for 6^18 h. The mating culture was then
plated on 100-mm, SD/3Leu/3Trp and SD/3Leu/3Trp/3His/+5
mM 3-AT plates. The plates were incubated at 30‡C for 3^5 days
to allow diploid cells to form visible colonies. Colonies were scored
for growth on the SD/3Leu/3Trp/3His/+3-AT plates.
2.6. Antibody production against SLPI-BP C-terminal peptide
Antiserum was raised in rabbits using a peptide corresponding to a
sequence in the C-terminus of SLPI-BP (CESTGSQEQKSGVW) con-
jugated to keyhole limpet hemocyanin. The speci¢city of the antibody
towards the SLPI-BP was determined by Western blot analysis using
T7-SLPI-BP transfected COS cells. As control, parental COS cells or
mock transfected cells were used.
2.7. Transient transfection and S-protein pulldown assays
COS cells were transfected with 2 Wg of the indicated plasmids
(pCI-neo/His-S-SLPI and/or pCI-neo/T7-SLPI-BP) using 6 Wl of lipo-
fectamine reagent as previously described [7]. Forty-eight h after
transfection, total cell lysates were obtained by extracting the cells
with 200 Wl lysis bu¡er A (50 mM HEPES, pH 7.5, 150 mM NaCl,
10% glycerol, 1% Triton X-100, 1.5 mM MgCl2, 10 Wg/ml aprotinin,
10 Wg/ml leupeptin, 1 mM phenylmethylsulfonyl £uoride, 200 WM
sodium orthovanadate, 0.01 M sodium £uoride and 1 mM EGTA)
at 4‡C for 30 min. The lysates were cleared by centrifugation.
S-Protein pulldown assays were performed by mixing 400 Wl of cell
lysates with 50 Wl of agarose-conjugated S-protein at 4‡C for 2 h.
After three washes with the lysis bu¡er A, the pellets were dissolved
in 1Usodium dodecyl sulfate (SDS) sample bu¡er and the superna-
tants were subjected to Western blot analysis using an anti-C/304^318
antibody.
2.8. Western blot analysis
The expression of protein was detected by the enhanced chemilu-
minescence (ECL) method as described previously [8]. Brie£y, cell
lysates were fractionated on a 12% SDS^polyacrylamide gel. After
electrotransferring to a PVDF membrane, the non-speci¢c binding
sites were blocked by immersing the membrane into a blocking bu¡er
containing 5% dry milk in phosphate-bu¡ered saline and 0.1% Tween
20 (PBS-T) at room temperature for 2 h. Then the membrane was
incubated with the primary antibody diluted in the blocking bu¡er for
1 h. After washing the membrane for 20 min with PBS-T, the horse-
radish peroxidase-labeled secondary antibody was added and incu-
bated for 1 h at room temperature. After the ¢nal wash, the detection
reagents were mixed and applied to cover the surface of the mem-
brane. For autoradiography, ¢lm was exposed as described by the
manufacturer.
3. Results
3.1. Isolation of SLPI-BP in a yeast two-hybrid library
screening
To identify leukocytic proteins that interact with salivary
SLPI, we used the in vivo yeast two-hybrid system. A con-
struct with GAL4 BD fused with SLPI (i.e. pAS2-1/SLPI) was
co-transformed with the human peripheral blood leukocyte
cDNA library fused with GAL4 AD into yeast strain CG-
1945. Positive clones were selected by auxotrophy for histidine
and by expression of L-galactosidase. Approximately 3U106
independent clones were screened. Initial screenings of the
leukocyte cDNA library had generated 50 putative His
clones. Among these primary His clones, the true interacting
clones were screened for expression of the second reconsti-
tuted reporter gene (LacZ) using the L-galactosidase assay.
Six clones exhibiting HisLacZ positive interaction pheno-
types were identi¢ed. DNA sequencing analysis revealed that
¢ve of the HisLacZ clones (designated His 2, 8, 9, 13 and
14) are of the same cDNA species with di¡erent lengths of the
untranslated and/or translated regions (Fig. 1). BLAST se-
Fig. 1. Alignment of the nucleic acid sequences of the HisLacZ SLPI-BP clones and scramblase (access number AF008445). Numbers above
the sequence refer to the nucleotide numbering of scramblase. The solid bars indicate regions of predicted translated sequence, while the line re-
gions denote the predicted untranslated region.
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quence similarity searching of the Genbank database revealed
that these ¢ve clones encoded the human scramblase protein
(Fig. 2). With the exception of clone His-13, which encoded
an N-terminal truncated protein (deletion of amino acids 1^
76), the other four clones encoded the full-length human
scramblase with di¡erent lengths in the 5P- and/or 3P-untrans-
lated regions (Fig. 1). In addition, all of the ¢ve clones showed
in-frame fusion with the GAL4 AD (data not shown), sug-
gesting the correct expression of SLPI-BP/scramblase protein
in these constructs. With most of the true positive clones
encoding scramblase cDNA, these results strongly suggest
that scramblase is a major SLPI-BP.
3.2. Veri¢cation of positive two-hybrid interactions
The speci¢city of the interaction between SLPI and SLPI-
BP was further veri¢ed by the following experiments (Table 1
and Fig. 3). At ¢rst, we employed three bait plasmids (pAS2-1
expressing GAL4-DNA-BD, pAS2-1/SLPI expressing GAL4-
DNA-BD/SLPI fusion protein, and pLAM5P expressing
GAL4-DNA-BD/human laminin C fusion protein) and four
prey plasmids (pGAD10 expressing GAL-AD, pGAD10/li-
brary expressing GAL-AD/leukocyte library hybrids, pCL-1
expressing full-length GAL-AD, and pGAD10/SLPI-BP ex-
pressing GAL4-AD/SLPI-BP fusion protein) in a set of yeast
two-hybrid assays. The SLPI-BP cDNAs were from clones
His-2, 8, 9, 13 or 14, respectively. Our results showed that
when the yeast strain CG-1945 containing pAS2-1 was trans-
formed with either pGAD10 or pGAD10/library, the trans-
formants did not grow on histidine-free synthetic dextrose
(SD/3His) plates (Table 1). Furthermore, yeast harboring a
combination of pAS2-1/SLPI and pGAD10 also did not grow
on SD/3His plates. In contrast, yeast containing a combina-
tion of pAS2-1/SLPI and pGAD10/SLPI-BP grew on SD/
3His plates (Table 1).
We then determined the L-galactosidase activity in yeast
CG-1945 strains that harbored the same combinations of plas-
mids as described in Table 1 and Fig. 3. The yeast transform-
ants that contain either (i) pAS2-1/SLPI and pGAD10/SLPI-
BP, (ii) pCL-1, (iii) pVA3-1 and pTD1-1 or (iv) pLAM5P with
pCL1, expressed L-galactosidase activity (Fig. 3, lanes 6 and
Fig. 2. DNA sequence of a representative HisLacZ SLPI-BP clone. The start codon (ATG) and stop codon (TAG) are denoted in bold.
Fig. 3. Association of salivary SLPI and SLPI-BP from leukocyte in the yeast two-hybrid system. The LacZ phenotype expression of the yeast
transformants were analyzed in a L-galactosidase assay. Upper and lower rows are duplicates of the same clones. A: Filter paper patched with
various yeast colonies to be tested for LacZ phenotype. B: Yeast cells were permeabilized with liquid nitrogen followed by incubation with X-
gal on ¢lter at 30‡C. The L-galactosidase-producing colonies appeared as dark patches in the ¢gure. The colonies are as follows: 1, pAS2-1/
SLPI only; 2, pAS2-1+pGAD10; 3, pAS2-1/SLPI+pGAD10; 4, pGAD10/SLPI-BP; 5, pGAD10 only; 6, pAS2-1/SLPI+pGAD10/SLPI-BP; 7,
pGAD10/SLPI-BP; 8, pAS2-1+pGAD10/SLPI-BP; 9, pCL1, a positive control plasmid encoding the full-length, wild-type GAL4 protein; 10,
pVA3-1+pTD1-1, which encode for a known interacting protein pair, i.e. a DNA-BD/murine p53 protein and an AD/SV40 large T-antigen pro-
tein, respectively; 11, pLAM5P+pCL1. The pLAM5P is a false-positive detection plasmid which encodes a DNA-BD/human laminin C protein
in pAS2-1; 12, pLAM5P+pGAD10/SLPI-BP. The data of pGAD10/SLPI-BP shown here were from clone His-9. Similar results were obtained
from clones His-2, 8, 13 and 14 (data not shown).
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9^11, respectively). Other yeast transformants tested did not
express LacZ phenotype. These results indicated that SLPI
speci¢cally interacts with SLPI-BP/scramblase.
3.3. In vivo association of SLPI with SLPI-BP
To obtain another indication of the protein^protein inter-
action suggested by the two-hybrid system, we examined the
ability of the protein product of SLPI to ‘pull’ down SLPI-BP
in mammalian cell lysates. At ¢rst, we constructed SLPI-BP
and SLPI mammalian expression plasmids, pCI-neo/T7-SLPI-
BP and pCI-neo/His-S-SLPI, respectively. By design, the
SLPI-BP was expressed as a T7-tag fusion protein that could
be detected by either the anti-T7 or the anti-SLPI-BP peptide
antibody (anti-C/304^318) generated in our laboratory. On
the other hand, SLPI was expressed as a His6X and S-tag
fusion protein that could be detected by either the anti-His-
tag, anti-S-tag, or anti-SLPI antibody. The expression of re-
combinant T7-SLPI-BP fusion protein was demonstrated in a
transient transfection experiment (Fig. 4). After transient
transfection of pCI-neo/T7-SLPI-BP into COS cells, a molec-
ular mass of approximately 38-kDa protein was observed for
T7-tag SLPI-BP using the anti-C/304^318 antibody (Fig. 4B,
lanes 2 and 4). Such protein was absent in the mock trans-
fected cells (Fig. 4B, lane 1), or in cells transfected with pCI-
neo/His-S-SLPI (Fig. 4B, lane 3).
To examine the interaction between SLPI-BP and SLPI,
COS cells were cotransfected with the following plasmid com-
binations: (1) pCI-neo; (2) pCI-neo/T7-SLPI-BP+pCI-neo;
(3) pCI-neo/His-S-SLPI+pCI-neo or (4) pCI-neo/T7-SLPI-
BP+pCI-neo/His-S-SLPI. S-Protein pulldown assays were per-
formed using agarose bead-bound S-protein. Bound proteins
were subjected to Western blotting using the anti-C/304^318
antibody (Fig. 4B). We have shown that SLPI-BP was ‘pulled’
down by S-protein when S-tagged SLPI was co-expressed in
the cells (Fig. 4B, lane 8). However, when SLPI-BP was ex-
pressed in the absence of S-tagged SLPI, as in the pCI-neo+
pCI-neo/T7-SLPI-BP cotransfected cells (Fig. 4B, lane 2), no
SLPI-BP protein was detected in the pulldown mixture (Fig.
4B, lane 6). These results indicate that SLPI speci¢cally inter-
acts with scramblase in vivo.
4. Discussion
In this study, we performed a yeast two-hybrid screening
using human peripheral blood leukocyte cDNA for candidate
proteins that interact with salivary SLPI. Our results suggest
that the major SLPI-BP is the human scramblase, a novel 37-
kDa integral membrane protein that is involved in the dynam-
ic movement of membrane PLs [9,10]. To the best of our
knowledge, the complex between scramblase and a protease
inhibitor superfamily has not yet been reported. Thus, our
data represent the ¢rst report for the identi¢cation of scram-
blase as a SLPI-BP.
The possibility of interaction between SLPI and scramblase
seems to be reasonable because ¢ve out of six clones identi¢ed
encoded the same gene product. The interaction was ¢rst
veri¢ed by yeast two-hybrid screening in a yeast mating assay
using plasmids rescued separately from the HisLacZ yeast
clones. Subsequent S-protein pulldown experiments provided
another line of evidence for such interaction. In this experi-
Table 1
HIS3 reporter gene expression and L-galactosidase activities of yeast strains harboring various combinations of GAL4 DNA-BD and -AD fu-
sion plasmids
No. Plasmid 1 (DNA-BD) Plasmid 2 (AD) His3 phenotype LacZ phenotype
1 pAS2-1 (DNA-BD/no insert) pGAD10 (AD only) no growth white
2 pAS2-1/SLPI (DNA-BD/SLPI) pGAD10 (AD only) no growth white
3 pAS2-1 pGAD10/library no growth white
4 pLAM5P-1 (DNA-BD/control) pGAD10/library no growth white
5 blank pCL-1 (full-length GAL4) no growth blue
6 pAS2-1/SLPI pGAD10/SLPI-BP (clones #2, 8, 9, 13 and 14) positive growth blue
Fig. 4. Interaction of SLPI and SLPI-BP in vivo. The COS cells
were transiently transfected with either pCI-neo (lanes 1 and 5),
pCI-neo/T7-SLPI-BP+pCI-neo (lanes 2 and 6), pCI-neo/His-S-
SLPI+pCI-neo (lanes 3 and 7) or pCI-neo/T7-SLPI-BP+pCI-neo/
His-S-SLPI (lanes 4 and 8). After 48 h, the cellular proteins without
(lanes 1 to 4) or with (lanes 5 to 8) incubation with agarose-conju-
gated S-protein were fractionated on a 12% SDS^PAGE and elec-
trotransferred onto a PVDF membrane. A: Blot was stained with
Ponceau S to illustrate the equal loading of cell lysates between
lanes 1, 2, 3 and 4. B: The same membrane was incubated with an
anti-C/304-318 antibody against a C-terminal peptide of SLPI-BP.
The sizes of a pre-stained marker are shown in lane 9.
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ment, SLPI-BP was ‘pulled’ down from COS cells co-express-
ing exogenous S-tag SLPI with an agarose-conjugated S-pro-
tein, indicating that the complex of SLPI and SLPI-BP exists
in mammalian cells. Although the interacting motifs between
these two proteins need to be further identi¢ed, DNA se-
quencing analysis revealed that one of the ¢ve interacting
clones (clone His-13) encoded an N-terminal truncated scram-
blase, suggesting that the 76 amino acids of the N-terminus of
SLPI-BP is not critical for binding to SLPI.
The precise biological function of the SLPI-scramblase in-
teraction is presently unclear. Numerous studies [4,11^14]
have shown that SLPI protects cultured mononuclear cells
against HIV infection at an early stage that occurs after viral
binding but before viral reverse transcription. HIV-1 gains
entry into susceptible cells by means of fusion of viral and
cellular membranes. The fusion process is a complex phenom-
enon that involves an entire range of biochemical and physical
interactions. Several studies have implicated a role of mem-
brane PL in viral entry into the host cells. A leucine zipper-
like sequence corresponding to the residues 789^815 from the
cytoplasmic tail of the viral gp41 protein was shown to bind
and perturb PL bilayers of the infected cells [15]. In addition,
fusion peptides derived from the HIV-1 gp41 have been
shown to associate with PL membranes and inhibited cell^
cell fusion [16]. Thus, any molecules that a¡ect PL movement
may modulate HIV-1 infection. It is important to notice that
since scramblase may regulate the dynamic £ip-£op movement
of the PL bilayer of cell membrane, we envisage that scram-
blase may be directly or indirectly involved with the entry of
HIV into host cells. In this context, the identity of scramblase
as the SLPI-BP appears to ¢t well with the current model of
SLPI’s action on the inhibition of HIV-1 infection. However,
whether SLPI interacts with scramblase at the cell surface or
intra-cellularly is presently unclear. Based on a previous study
which suggested that SLPI might attain its anti-HIV activity
by binding to a host cell surface molecule [4], we postulate
that SLPI may bind speci¢cally to the extracellular domain
(C-terminal to the transmembrane domain) of scramblase and
that the SLPI^scramblase interaction may stabilize the mem-
brane PL bilayer such that fusion of HIV with host cellular
membrane will be blocked. We are currently determining how
and at which step such association could a¡ect HIV infection.
When these aspects of scramblase action are made clear, we
may obtain a new twist in the mechanism of SLPI-induced
inhibition of HIV-1 membrane fusion. Such information can
ultimately lead to novel therapeutic strategies against HIV
and similar viruses.
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